The targeted drugs act against vascular endothelial growth factor (VEGF) and other important proteins (tyrosine kinases) that enable cancer cell growth and survival, but treatment response is varied; and at best, these targeted drugs can only slow the growth of the cancer for a time but do not actually cure kidney cancer. Here, VEGFA is linked to kidney cancer.